Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems
- PMID: 27771389
- DOI: 10.1016/j.antiviral.2016.10.007
Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems
Abstract
Lassa virus (LASV) and Ebola virus (EBOV) infections are important global health issues resulting in significant morbidity and mortality. While several promising drug and vaccine trials for EBOV are ongoing, options for LASV infection are currently limited to ribavirin treatment. A major factor impeding the development of antiviral compounds to treat these infections is the need to manipulate the virus under BSL-4 containment, limiting research to a few institutes worldwide. Here we describe the development of a novel LASV minigenome assay based on the ambisense LASV S segment genome, with authentic terminal untranslated regions flanking a ZsGreen (ZsG) fluorescent reporter protein and a Gaussia princeps luciferase (gLuc) reporter gene. This assay, along with a similar previously established EBOV minigenome, was optimized for high-throughput screening (HTS) of potential antiviral compounds under BSL-2 containment. In addition, we rescued a recombinant LASV expressing ZsG, which, in conjunction with a recombinant EBOV reporter virus, was used to confirm any potential antiviral hits in vitro. Combining an initial screen to identify potential antiviral compounds at BSL-2 containment before progressing to HTS with infectious virus will reduce the amount of expensive and technically challenging BSL-4 containment research. Using these assays, we identified 6-azauridine as having anti-LASV activity, and demonstrated its anti-EBOV activity in human cells. We further identified 2'-deoxy-2'-fluorocytidine as having potent anti-LASV activity, with an EC50 value 10 times lower than that of ribavirin.
Published by Elsevier B.V.
Similar articles
-
Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.J Virol. 2019 Apr 3;93(8):e02185-18. doi: 10.1128/JVI.02185-18. Print 2019 Apr 15. J Virol. 2019. PMID: 30700611 Free PMC article.
-
Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays.Viruses. 2018 Nov 20;10(11):655. doi: 10.3390/v10110655. Viruses. 2018. PMID: 30463334 Free PMC article.
-
Current research for a vaccine against Lassa hemorrhagic fever virus.Drug Des Devel Ther. 2018 Aug 14;12:2519-2527. doi: 10.2147/DDDT.S147276. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30147299 Free PMC article. Review.
-
An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.Antiviral Res. 2017 Oct;146:21-27. doi: 10.1016/j.antiviral.2017.08.005. Epub 2017 Aug 12. Antiviral Res. 2017. PMID: 28807685 Free PMC article.
-
Immunobiology of Ebola and Lassa virus infections.Nat Rev Immunol. 2017 Mar;17(3):195-207. doi: 10.1038/nri.2016.138. Epub 2017 Jan 23. Nat Rev Immunol. 2017. PMID: 28111475 Review.
Cited by
-
Pseudovirus-Based Systems for Screening Natural Antiviral Agents: A Comprehensive Review.Int J Mol Sci. 2024 May 10;25(10):5188. doi: 10.3390/ijms25105188. Int J Mol Sci. 2024. PMID: 38791226 Free PMC article. Review.
-
Treatment of highly virulent mammarenavirus infections-status quo and future directions.Expert Opin Drug Discov. 2024 May;19(5):537-551. doi: 10.1080/17460441.2024.2340494. Epub 2024 Apr 12. Expert Opin Drug Discov. 2024. PMID: 38606475 Review.
-
Heat-Denatured Lysozyme is a Novel Potential Non-alcoholic Disinfectant Against Respiratory Virus.Food Environ Virol. 2023 Sep;15(3):212-223. doi: 10.1007/s12560-023-09556-1. Epub 2023 May 8. Food Environ Virol. 2023. PMID: 37155116 Free PMC article.
-
Visualizing lymphocytic choriomeningitis virus infection in cells and living mice.iScience. 2022 Sep 7;25(10):105090. doi: 10.1016/j.isci.2022.105090. eCollection 2022 Oct 21. iScience. 2022. PMID: 36185356 Free PMC article.
-
Establishment of Recombinant Trisegmented Mopeia Virus Expressing Two Reporter Genes for Screening of Mammarenavirus Inhibitors.Viruses. 2022 Aug 25;14(9):1869. doi: 10.3390/v14091869. Viruses. 2022. PMID: 36146676 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical